Posted by Michael Wonder on 06 May 2024
MannKind receives US FDA fast track designation for clofazimine inhalation suspension for the treatment of non-tuberculous mycobacterial lung disease
6 May 2024 - MannKind Corporation announced today that the US FDA has granted fast track designation of clofazimine inhalation suspension (MNKD-101) for the treatment of non-tuberculous mycobacterial lung disease.
The US FDA previously designated clofazimine inhalation suspension as both an orphan drug and a qualified infectious disease product for the treatment of pulmonary non-tuberculous mycobacterial infections.
